Clin Lab. 2024 Aug 1;70(8). doi: 10.7754/Clin.Lab.2024.240147.
Famotidine is a competitive histamine H-receptor antagonist that reduces the formation of stomach acid and is used to treat gastrointestinal disorders associated with acid reflux, gastroesophageal reflux disease, duodenal ulcer, gastric ulcer, and pathological hypersecretory disorders. This study is designed to investigate the possible neuroprotective effects of the ranolazine scopolamine-induced Alzheimer's disease-like feature in a mouse model.
Mice were divided equally into five groups (ten mice per group), including control group and induction group. The mice in the induction group were administered scopolamine 1 mg/kg i.p., once daily for 7 days, to induce features similar to Alzheimer's disease. The mice in the remaining three treatment groups were given tested medications prophylactically for 14 days. After that the induction was carried out with scopolamine 1 mg/kg i.p., once daily, while the tested medication dosages were continued for an additional 7 days. These treatment groups included: the donepezil group (5 mg/kg/day), the famotidine group (40 mg/kg/day) and the combined group with donepezil (5 mg/kg/day) and famotidine (40 mg/kg/day); all were administrated i.p., once daily. Behavioral parameters were assessed, among others with the Y-maze test and novel object recognition test, and the inflammatory cytokines and oxidative stress parameters were assessed as well.
Famotidine exhibits significant improvements in behavior and memory, level of oxidative stress parame-ter, and inflammatory cytokines.
Famotidine and its combination at prescribed doses in the current study improved learning and memory impairments in mice model of Alzheimer's disease probably via their antioxidant and anti-inflammatory properties confirmed by a significant increase in antioxidant mediator and a significant decrease in oxidative stress marker and inflammatory cytokines.
法莫替丁是一种竞争性组胺 H 受体拮抗剂，可减少胃酸的形成，用于治疗与胃酸反流、胃食管反流病、十二指肠溃疡、胃溃疡和病理性高分泌紊乱相关的胃肠道疾病。本研究旨在探讨雷诺嗪对 scopolamine 诱导的阿尔茨海默病样特征的可能神经保护作用。
将小鼠平均分为五组（每组 10 只），包括对照组和诱导组。诱导组小鼠腹腔注射 scopolamine 1mg/kg，每天 1 次，连续 7 天，诱导类似阿尔茨海默病的特征。其余三组治疗组预防性给予受试药物 14 天。然后，用 scopolamine 1mg/kg 腹腔注射，每天 1 次，继续给药 7 天，诱导。这些治疗组包括：多奈哌齐组（5mg/kg/天）、法莫替丁组（40mg/kg/天）和多奈哌齐（5mg/kg/天）和法莫替丁（40mg/kg/天）联合组；均腹腔注射，每天 1 次。评估行为参数，包括 Y 迷宫测试和新物体识别测试，以及评估炎症细胞因子和氧化应激参数。
法莫替丁在行为和记忆、氧化应激参数水平和炎症细胞因子方面均有显著改善。
法莫替丁及其在当前研究中以规定剂量联合使用，可能通过其抗氧化和抗炎特性改善阿尔茨海默病小鼠模型的学习和记忆障碍，这一点得到了抗氧化介质的显著增加和氧化应激标志物和炎症细胞因子的显著减少的证实。
